RELUKO Q Code: Q5125

Drug & Product Overview

HCPCS Descriptor Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram

HCPCS Added Date October 1, 2022

Manufacturer Amneal Biosciences

Route of Administration Intravenous, Subcutaneous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution

About RELUKO

Reluko is a medication aligned to the HCPCS Q Code: Q5125 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology Colony Stimulating Factor, it is administered via the intravenous or subcutaneous routes and manufactured by Amneal Biosciences.

According to CMS Drug Use Information: Filgrastim is a man-made version of a certain natural substance made by your body. It is used to help your body make more white blood cells. White blood cells are important to help you fight off infections. Filgrastim is given to people whose ability to make white blood cells is reduced (for instance, due to chemotherapy, chronic neutropenia, or exposure to large amounts of radiation). It is also used in certain treatment procedures (such as bone marrow/stem cell transplant). This monograph is about the following filgrastim products: filgrastim, filgrastim-aafi, filgrastim-ayow, filgrastim-laha, filgrastim-sndz, filgrastim-txid, and tbo-filgrastim.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
70121-1568-01	Releuko	Amneal Pharmaceuticals LLC	300	300 MCG / 0.5 ML
70121-1568-07	Releuko	Amneal Pharmaceuticals LLC	3000	300 MCG / 0.5 ML
70121-1570-01	Releuko	Amneal Pharmaceuticals LLC	480	480 MCG / 0.8 ML
70121-1570-07	Releuko	Amneal Pharmaceuticals LLC	4800	480 MCG / 0.8 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

RELUKO Pricing & Reimbursement

Q5125 Private Payer Reimbursement

$0.88 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Filgrastim Biosimilar Information:

RELUKO Approval Date: February 25, 2022

Product Name	HCPCS Code	Active Ingredient	BLA Type
Neupogen	J1442	Filgrastim	351(a) Originator Product
Zarxio	Q5101	Filgrastim	351(k) Biosimilar
Nivestym	Q5110	Filgrastim	351(k) Biosimilar
Releuko	Q5125	Filgrastim	351(k) Biosimilar
Nypozi	Q5148	Filgrastim	351(k) Biosimilar
Filkri	Q5172	Filgrastim	351(k) Biosimilar

RELUKO Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 11.22%

Avg. Days to File 5.8days

Avg. Days to Pay 21.5days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q5125 claims analytics on FocalPoint →

RELUKO CPT Administration Codes

CPT Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic

JW / JZ modifiers apply

CMS has identified Reluko (Q5125) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

RELUKO Medically Unlikely Edits (MUE)

The most billing units of Q5125 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mcg.

Practitioner Office & Hospital Outpatient

1,800 units / day

= 1,800 mcg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

RELUKO Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Acute myeloid leukemia receiving induction or consolidation chemotherapy Autologous peripheral blood progenitor cell collection and therapy Hematopoietic syndrome of acute radiation syndrome Nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs Nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation Severe chronic neutropenia — congenital neutropenia Severe chronic neutropenia — idiopathic or cyclic neutropenia

Drug Class

Granulocyte Colony-Stimulating Factor [CS]Increased Myeloid Cell Production [PE]Leukocyte Growth Factor [EPC]

Frequently Asked Questions

Is there an available Reluko billing and coding guide?

Billing and coding information for RELUKO can be found through Amneal Biosciences. Visit Here →

Are there any available Reluko patient assistance programs?

RELUKO patient assistance information can be found through Amneal Biosciences. Visit Here →

Where can I find Reluko prescribing information?

RELUKO prescribing information can be found at the link below: Visit Here →

Where can I find Reluko side effect information?

Our team has not yet identified a source of side effects information for RELUKO. Please check back in a few weeks.

Does billing RELUKO require JZ/JW wastage modifiers?

CMS has identified RELUKO(Q5125) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.